DiaMedica Therapeutics Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $24.6M | $19.1M | $13.1M | $7.8M | $8.8M | $8.2M | $7.9M |
| SG&A Expense | — | $9.8M | $7.6M | $8.2M | $6.2M | $4.9M | $4.5M | $3.7M |
| Operating Income | — | $-34.4M | $-26.7M | $-21.3M | $-14.0M | $-13.6M | $-12.7M | $-11.6M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-32.7M | $-24.4M | $-19.3M | $-13.6M | $-13.6M | $-12.3M | $-10.6M |
| Income Tax Expense | — | $28.0K | $30.0K | $43.0K | $28.0K | $28.0K | $27.0K | $31.0K |
| Net Income | — | $-32.8M | $-24.4M | $-19.4M | $-13.7M | $-13.6M | $-12.3M | $-10.6M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-0.70 | $-0.60 | $-0.60 | $-0.52 | $-0.65 | $-0.78 | $-0.89 |
| EPS (Diluted) | — | — | — | — | — | $-0.65 | $-0.78 | $-0.89 |
| Shares Outstanding (Basic) | 53.9M | 47.0M | 40.4M | 32.6M | 26.4M | 20.8M | 18.7M | 12.0M |
| Shares Outstanding (Diluted) | 53.9M | 47.0M | 40.4M | 32.6M | 26.4M | 20.8M | 18.7M | 12.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |